Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 8/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 3/20 | 0.41 |
| ▸ | USP2 | O75604 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | GBA1 | P04062 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27726789 | 0.77 | HTT (0.57) | HTTSMN1; SMN2KDM4EALDH1A1LMNA | |
| SCHEMBL11280402 | 0.74 | HTT (0.61) | HTTSMN1; SMN2L3MBTL1KDM4EALDH1A1 | |
| SCHEMBL3831791 | 0.74 | NCF1 (0.61) | HTTSMN1; SMN2L3MBTL1KDM4ELMNA | |
| SCHEMBL3833749 | 0.74 | NCF1 (0.61) | HTTSMN1; SMN2L3MBTL1KDM4ELMNA | |
| SCHEMBL24287287 | 0.73 | KDM4E (0.54) | SMN1; SMN2KDM4EALDH1A1LMNAMAPT | |
| SCHEMBL29516537 | 0.73 | KDM4E (0.54) | SMN1; SMN2KDM4EALDH1A1LMNAMAPT | |
| SCHEMBL5670238 | 0.72 | HDAC1 (0.53) | HTTSMN1; SMN2KDM4EALDH1A1LMNA | |
| SCHEMBL30483849 | 0.72 | HDAC1 (0.53) | HTTSMN1; SMN2KDM4EALDH1A1LMNA | |
| SCHEMBL9495292 | 0.72 | MAOA (0.47) | SMN1; SMN2KDM4EALDH1A1LMNAMAPT | |
| SCHEMBL1776856 | 0.71 | NCF1 (0.61) | HTTLMNAHTR6PKMUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7943639-B2 | Such as 6-benzenesulfonyl-4-piperazin-1-yl-quinoline hydrochloride; for treatment of central nervous system and/or 5- HT6 receptor related disorders; for weight gain/loss | PROXIMAGEN LIMITED (GB) | 2011-05-17 | — | — | US | disclosed |
| EP-1897876-A2 | Compounds useful for the treatment of obesity, type II diabetes and CNS disorders | Biovitrum AB (publ) (SE) | 2008-03-12 | — | — | EP | disclosed |
| CN-101081845-A | Substituted sulphone and sulphonamide compounds useful for the treatment of obesity, type II diabetes and cns disorders | BIOVITRUM AB (SE) | 2007-12-05 | — | — | CN | disclosed |
| CN-1907982-A | New compounds useful for the treatment of obesity,type II diabetes and CNS disorders | BIOVITRUM AB (SE) | 2007-02-07 | — | — | CN | disclosed |
| CN-1662521-A | Novel compounds useful for the treatment of obesity, type II diabetes and CNS disorders | BIOVITRUM AB (SE) | 2005-08-31 | — | — | CN | disclosed |
| EP-1513828-A1 | NEW COMPOUNDS USEFUL FOR THE TREATMENT OF OBESITY, TYPE II DIABETES AND CNS DISORDERS | Biovitrum AB (SE) | 2005-03-16 | — | — | EP | disclosed |
| US-20040024210-A1 | New compounds | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2004-02-05 | — | — | US | disclosed |
| WO-2004000828-A1 | NEW COMPOUNDS USEFUL FOR THE TREATMENT OF OBESITY, TYPE II DIABETES AND CNS DISORDERS | BIOVITRUM AB (SE) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024210-A1 | New compounds | SULT1E1, SULT2A1, SULT1A1 | HTT 2558/4885SMN1; SMN2 960/4885L3MBTL1 3904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.